BACKGROUND AND OBJECTIVES
We aimed to define the cure rate in patients with colorectal liver metastases (CRLM) and concomitant extrahepatic disease (EHD) on the 5‐year disease‐free survival (DFS) after surgery, and identify the factors for predicting a cure.
METHODS
Patients who underwent hepatectomy for CRLM with concomitant EHD were identified. Those followed for >5 years after surgery were enrolled. A cure was defined as DFS of >5 years after the last curative surgery.
RESULTS
A cure was achieved in 24/175 (13%) patients (intention‐to‐treat [ITT] cohort), and 22/109 (19%) patients who underwent complete resection for both hepatic and extrahepatic metastases (EHD resection cohort). A multivariate analysis identified primary T1‐2 (relative risk [RR] 47.4, P = 0.0001), metachronous metastasis (RR 4.9, P = 0.026), carbohydrate antigen 19‐9 (CA19‐9) ≤37 U/mL (RR 8.37, P = 0.015), number of liver and EHD tumors (RR 11.2, P = 0.0058), and non‐incidental EHD diagnosis (RR 8.41, P = 0.018) as independent factors that predicted a cure in the ITT cohort; and primary T1‐2 (RR 22.2, P = 0.013), primary N0 (RR 4.42, P = 0.031), metachronous metastasis (RR 6.48, P = 0.013), and CA19‐9 ≤37 U/mL (RR 27.4, P = 0.012) in the EHD resection cohort.
CONCLUSIONS
Even when concomitant EHD is present, a potential of cure could be achieved with aggressive oncosurgical approach.